Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company based in Cambridge, MA. They are a trusted leader in the renal community, dedicated to delivering unique products to people with kidney disease. Akebia's team works tirelessly to address complications of kidney disease and is committed to advancing new hope for those affected by this serious and life-altering illness.
With a focus on research and development, Akebia is at the forefront of innovation in the field of kidney disease. They have developed a commercially available medicine and a late-stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) called vadadustat, which is based on Nobel Prize-winning science. While vadadustat is approved for use in 34 countries, it has not yet received approval from the U.S. Food and Drug Administration.
Generated from the website